Dipartimento di Ingegneria Elettrica

Contenuti del sito

Menu di navigazione - Torna all'inizio


Contenuto della pagina - Torna all'inizio


Fabio Blandini

Professore
Sede:
Fondazione Mondino
Telefono0382-380202
Fax0382-380414
Orari di ricevimentoSu appuntamento
Insegnamenti- Neuropharmacology (MSc PSYCHOLOGY, NEUROSCIENCE AND HUMAN SCIENCES) - Neuropatologia (L.M. Neurobiologia)

ATTIVITA’ DI RICERCA

Neurobiologia e neurofarmacologia della malattia di Parkinson, con particolare riferimento agli aspetti patogenetici e fisiopatologici e all’individuazione di bio-marcatori e terapie innovative
PubblicazioniPubblicazioni ultimi tre anni (2017-2019 + parziale 2020) 1: Avenali M, Blandini F, Cerri S. Glucocerebrosidase Defects as a Major Risk Factor for Parkinson's Disease. Front Aging Neurosci. 2020 Apr 21;12:97. doi: 10.3389/fnagi.2020.00097. PMID: 32372943; PMCID: PMC7186450. 2: Pellegrini C, Ippolito C, Segnani C, Dolfi A, Errede M, Virgintino D, Fornai M, Antonioli L, Garelli F, Nericcio A, Colucci R, Cerri S, Blandini F, Blandizzi C, Bernardini N. Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration. Neurobiol Dis. 2020 Jun;139:104821. doi: 10.1016/j.nbd.2020.104821. Epub 2020 Feb 21. PMID: 32088380. 3: Avenali M, Toffoli M, Mullin S, McNeil A, Hughes DA, Mehta A, Blandini F, Schapira AHV. Evolution of prodromal parkinsonian features in a cohort of GBA mutation-positive individuals: a 6-year longitudinal study. J Neurol Neurosurg Psychiatry. 2019 Oct;90(10):1091-1097. doi: 10.1136/jnnp-2019-320394. Epub 2019 Jun 20. PMID: 31221723. 4: Giuliano C, Siani F, Mus L, Ghezzi C, Cerri S, Pacchetti B, Bigogno C, Blandini F. Neuroprotective effects of lignan 7-hydroxymatairesinol (HMR/lignan) in a rodent model of Parkinson's disease. Nutrition. 2020 Jan;69:110494. doi: 10.1016/j.nut.2019.04.006. Epub 2019 Apr 25. PMID: 31586482. 5: Fuzzati-Armentero MT, Cerri S, Blandini F. Peripheral-Central Neuroimmune Crosstalk in Parkinson's Disease: What Do Patients and Animal Models Tell Us? Front Neurol. 2019 Mar 19;10:232. doi: 10.3389/fneur.2019.00232. PMID: 30941089; PMCID: PMC6433876. 6: Cerri S, Mus L, Blandini F. Parkinson's Disease in Women and Men: What's the Difference? J Parkinsons Dis. 2019;9(3):501-515. doi: 10.3233/JPD-191683. PMID: 31282427; PMCID: PMC6700650. 7: Cerri S, Blandini F. Role of Autophagy in Parkinson's Disease. Curr Med Chem. 2019;26(20):3702-3718. doi: 10.2174/0929867325666180226094351. PMID: 29484979. 8: Blandini F, Cilia R, Cerri S, Pezzoli G, Schapira AHV, Mullin S, Lanciego JL. Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine. Mov Disord. 2019 Jan;34(1):9-21. doi: 10.1002/mds.27583. Epub 2018 Dec 27. PMID: 30589955. 9: Mus L, Siani F, Giuliano C, Ghezzi C, Cerri S, Blandini F. Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity. Neurobiol Dis. 2019 Apr;124:289-296. doi: 10.1016/j.nbd.2018.12.001. Epub 2018 Dec 4. PMID: 30521842. 10: Milanese C, Cerri S, Ulusoy A, Gornati SV, Plat A, Gabriels S, Blandini F, Di Monte DA, Hoeijmakers JH, Mastroberardino PG. Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson's disease. Cell Death Dis. 2018 Jul 26;9(8):818. doi: 10.1038/s41419-018-0848-7. PMID: 30050065; PMCID: PMC6062587. 11: Kustrimovic N, Comi C, Magistrelli L, Rasini E, Legnaro M, Bombelli R, Aleksic I, Blandini F, Minafra B, Riboldazzi G, Sturchio A, Mauri M, Bono G, Marino F, Cosentino M. Parkinson's disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients. J Neuroinflammation. 2018 Jul 12;15(1):205. doi: 10.1186/s12974-018-1248-8. PMID: 30001736; PMCID: PMC6044047. 12: Cerri S, Ghezzi C, Sampieri M, Siani F, Avenali M, Dornini G, Zangaglia R, Minafra B, Blandini F. The Exosomal/Total α-Synuclein Ratio in Plasma Is Associated With Glucocerebrosidase Activity and Correlates With Measures of Disease Severity in PD Patients. Front Cell Neurosci. 2018 May 18;12:125. doi: 10.3389/fncel.2018.00125. PMID: 29867358; PMCID: PMC5968118. 13: Rizzi N, Brunialti E, Cerri S, Cermisoni G, Levandis G, Cesari N, Maggi A, Blandini F, Ciana P. In vivo imaging of early signs of dopaminergic neuronal death in an animal model of Parkinson's disease. Neurobiol Dis. 2018 Jun;114:74-84. doi: 10.1016/j.nbd.2018.02.005. Epub 2018 Feb 24. PMID: 29486298. 14: Marcelli S, Corbo M, Iannuzzi F, Negri L, Blandini F, Nistico R, Feligioni M. The Involvement of Post-Translational Modifications in Alzheimer's Disease. Curr Alzheimer Res. 2018 Feb 22;15(4):313-335. doi: 10.2174/1567205014666170505095109. PMID: 28474569. 15: Milanese C, Tapias V, Gabriels S, Cerri S, Levandis G, Blandini F, Tresini M, Shiva S, Greenamyre JT, Gladwin MT, Mastroberardino PG. Mitochondrial Complex I Reversible S-Nitrosation Improves Bioenergetics and Is Protective in Parkinson's Disease. Antioxid Redox Signal. 2018 Jan 1;28(1):44-61. doi: 10.1089/ars.2017.6992. Epub 2017 Sep 21. PMID: 28816057; PMCID: PMC5749586. 16: Gandolfi D, Cerri S, Mapelli J, Polimeni M, Tritto S, Fuzzati-Armentero MT, Bigiani A, Blandini F, Mapelli L, D'Angelo E. Activation of the CREB/c-Fos Pathway during Long-Term Synaptic Plasticity in the Cerebellum Granular Layer. Front Cell Neurosci. 2017 Jun 28;11:184. doi: 10.3389/fncel.2017.00184. PMID: 28701927; PMCID: PMC5487453. 17: Greco R, Demartini C, Zanaboni AM, Blandini F, Amantea D, Tassorelli C. Endothelial nitric oxide synthase inhibition triggers inflammatory responses in the brain of male rats exposed to ischemia-reperfusion injury. J Neurosci Res. 2018 Jan;96(1):151-159. doi: 10.1002/jnr.24101. Epub 2017 Jun 13. PMID: 28609584. 18: Cerri S, Siani F, Blandini F. Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias. Expert Opin Investig Drugs. 2017 Jul;26(7):777-791. doi: 10.1080/13543784.2017.1333598. Epub 2017 Jun 1. PMID: 28535734. 19: Siani F, Greco R, Levandis G, Ghezzi C, Daviddi F, Demartini C, Vegeto E, Fuzzati-Armentero MT, Blandini F. Influence of Estrogen Modulation on Glia Activation in a Murine Model of Parkinson's Disease. Front Neurosci. 2017 May 31;11:306. doi: 10.3389/fnins.2017.00306. PMID: 28620274; PMCID: PMC5449471. 20: Pellegrini C, Antonioli L, Colucci R, Tirotta E, Gentile D, Ippolito C, Segnani C, Levandis G, Cerri S, Blandini F, Barocelli E, Ballabeni V, Bernardini N, Blandizzi C, Fornai M. Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. Neuropharmacology. 2017 Sep 1;123:22-33. doi: 10.1016/j.neuropharm.2017.05.016. Epub 2017 May 17. PMID: 28526609. 21: Ambrosi G, Kustrimovic N, Siani F, Rasini E, Cerri S, Ghezzi C, Dicorato G, Caputo S, Marino F, Cosentino M, Blandini F. Complex Changes in the Innate and Adaptive Immunity Accompany Progressive Degeneration of the Nigrostriatal Pathway Induced by Intrastriatal Injection of 6-Hydroxydopamine in the Rat. Neurotox Res. 2017 Jul;32(1):71-81. doi: 10.1007/s12640-017-9712-2. Epub 2017 Mar 11. PMID: 28285346. 22: Greco R, Demartini C, Zanaboni AM, Blandini F, Amantea D, Tassorelli C. Modulation of cerebral RAGE expression following nitric oxide synthase inhibition in rats subjected to focal cerebral ischemia. Eur J Pharmacol. 2017 Apr 5;800:16-22. doi: 10.1016/j.ejphar.2017.02.008. Epub 2017 Feb 8. PMID: 28188764. 23: Greco R, Demartini C, Zanaboni AM, Redavide E, Pampalone S, Toldi J, Fülöp F, Blandini F, Nappi G, Sandrini G, Vécsei L, Tassorelli C. Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: Targets and anti-migraine mechanisms. Cephalalgia. 2017 Nov;37(13):1272-1284. doi: 10.1177/0333102416678000. Epub 2016 Nov 16. PMID: 27919017.
Collaborazioni- Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK (Prof. A.H. Schapira) - Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany (Prof. D. Di Monte) - Department of Genetics, Erasmus Medical Center, Rotterdam, The Netherlands (Dr. P.G. Mastroberardino) - Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona (Prof. J.L. Lanciego) - Center for Research in Medical Pharmacology, Università dell’Insubria, Varese (Prof. M. Cosentino) - Università del Piemonte Orientale, Novara (Prof. C. Comi) - Rete IRCCS Neurologia e Neuroriabilitazione, Ministero della Salute